Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The aim of the present study was to determine if late preterm AGA infants fed a formula enriched with higher protein and vitamin D in addition to nutrients postulated to be beneficial; [bovine milk fat globule membrane (MFGM) (13, 14) and butyrate (15)] results in improved rate of growth post discharge compared with infants fed a standard term formula.

Source: Introduction. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Double-blind reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Growth of late preterm infants fed nutrient-enriched formula to 120 days corrected age: A randomized controlled trial

Source: Article title.

This multicenter, randomized, double-blind, trial was approved by the Women's and Children's Health Network Human Research Ethics Committee (HREC/17/WCHN/84) and prospectively registered with the Australia New Zealand Clinical Trials Registry (ACTRN12618000092291).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Growth of late preterm infants fed nutrient-enriched formula to 120 days corrected age: A randomized controlled trial

Randomised controlled trial · Frontiers in Pediatrics · 2023

Original publication title

Growth of late preterm infants fed nutrient-enriched formula to 120 days corrected age: A randomized controlled trial

Karen P. Best; Lisa N. Yelland; Carmel T. Collins; Andrew J. McPhee; Geraint B. Rogers; Jocelyn Choo; Robert A. Gibson; Teresa Murguia-Peniche; Jojy Varghese; Timothy R. Cooper; Maria Makrides

© 2023 Best, Yelland, Collins, McPhee, Rogers, Choo, Gibson, Murguia-Peniche, Varghese, Cooper and Makrides.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

We saw no difference in rate of body weight gain between AGA late preterm infants fed NEF compared to STF. Results should be interpreted with caution due to small sample size.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

We aimed to compare the effects of nutrient-enriched formula with standard term formula on rate of body weight gain of late preterm infants appropriately grown for gestational age.

Source: Objectives

Abstract: Study design

A multi-center, randomized, controlled trial. Late preterm infants (34 to 37 weeks' gestation), with weight appropriate for gestational age (AGA), were randomized to nutrient enriched formula (NEF) with increased calories (22 kcal/30 ml) from protein, added bovine milk fat globule membrane, vitamin D and butyrate or standard term formula 20 kcal/30 ml (STF). Breastfed term infants were enrolled as an observational reference group (BFR). Primary outcome was rate of body weight gain from enrollment to 120 days corrected age (d/CA). Planned sample size was 100 infants per group.

Secondary outcomes included body composition, weight, head circumference and length gain, and medically confirmed adverse events to 365 d/CA.

Source: Study design

Abstract: Results

The trial was terminated early due to recruitment challenges and sample size was substantially reduced. 40 infants were randomized to NEF (n = 22) and STF (n = 18). 39 infants were enrolled in the BFR group. At 120 d/CA there was no evidence of a difference in weight gain between randomized groups (mean difference 1.77 g/day, 95% CI, −1.63 to 5.18, P = 0.31). Secondary outcomes showed a significant reduction in risk of infectious illness in the NEF group at 120 d/CA [relative risk 0.37 (95% CI, 0.16 to 0.85), P = 0.02].

Source: Results

Abstract: Conclusion

We saw no difference in rate of body weight gain between AGA late preterm infants fed NEF compared to STF. Results should be interpreted with caution due to small sample size.

Source: Conclusion
Authors’ abstract

Objectives

We aimed to compare the effects of nutrient-enriched formula with standard term formula on rate of body weight gain of late preterm infants appropriately grown for gestational age.

Study design

A multi-center, randomized, controlled trial. Late preterm infants (34 to 37 weeks' gestation), with weight appropriate for gestational age (AGA), were randomized to nutrient enriched formula (NEF) with increased calories (22 kcal/30 ml) from protein, added bovine milk fat globule membrane, vitamin D and butyrate or standard term formula 20 kcal/30 ml (STF). Breastfed term infants were enrolled as an observational reference group (BFR). Primary outcome was rate of body weight gain from enrollment to 120 days corrected age (d/CA). Planned sample size was 100 infants per group.

Secondary outcomes included body composition, weight, head circumference and length gain, and medically confirmed adverse events to 365 d/CA.

Results

The trial was terminated early due to recruitment challenges and sample size was substantially reduced. 40 infants were randomized to NEF (n = 22) and STF (n = 18). 39 infants were enrolled in the BFR group. At 120 d/CA there was no evidence of a difference in weight gain between randomized groups (mean difference 1.77 g/day, 95% CI, −1.63 to 5.18, P = 0.31). Secondary outcomes showed a significant reduction in risk of infectious illness in the NEF group at 120 d/CA [relative risk 0.37 (95% CI, 0.16 to 0.85), P = 0.02].

Conclusion

We saw no difference in rate of body weight gain between AGA late preterm infants fed NEF compared to STF. Results should be interpreted with caution due to small sample size.

Clinical Trial Registration

The Australia New Zealand Clinical Trials Registry (ACTRN 12618000092291). “mailto:maria.makrides@sahmri.com” maria.makrides@sahmri.com.

Publication and source details

Original title: Growth of late preterm infants fed nutrient-enriched formula to 120 days corrected age: A randomized controlled trial

Karen P. Best; Lisa N. Yelland; Carmel T. Collins; Andrew J. McPhee; Geraint B. Rogers; Jocelyn Choo; Robert A. Gibson; Teresa Murguia-Peniche; Jojy Varghese; Timothy R. Cooper; Maria Makrides

Frontiers in Pediatrics · 2023

Edited by: Amber Marie Milan, The University of Auckland, New Zealand

Reviewed by: Lisa Moloney, Academy of Nutrition and Dietetics Foundation, United States Rinawati Rohsiswatmo, RSUPN Dr. Cipto Mangunkusumo, Indonesia

* Correspondence: Maria Makrides maria.makrides@sahmri.com

Specialty Section: This article was submitted to Neonatology, a section of the journal Frontiers in Pediatrics

Abbreviations AMD, average mean difference; AGA, appropriately grown for gestational age; BFR, breastfeeding reference group; CA, corrected age; NEF, nutrient enriched formula; PMA, post-menstrual age; MFGM, milk fat globule membrane; SEIFA, socio-economic indexes for areas; STF, standard term formula.

© 2023 Best, Yelland, Collins, McPhee, Rogers, Choo, Gibson, Murguia-Peniche, Varghese, Cooper and Makrides.2023Best, Yelland, Collins, McPhee, Rogers, Choo, Gibson, Murguia-Peniche, Varghese, Cooper and Makrideshttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Mead Johnson & Company, LLC., 2400 West Lloyd Expressway, Evansville, Indiana 47721-000 funded the study, and monies were paid to the South Australian Health and Medical Research Institute (SAHMRI). Reckitt Benckiser LLC bought Mead Johnson during the study and continued to fund the study. The study was supported by the M.S. McLeod Research Fund, Women's and Children's Hospital Research Foundation (M.S. McLeod Post-Doctoral Fellowship to KPB), and by an NHMRC Fellowship (Principal Research Fellowship 1061704 to MM).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T07:14:46.439481+00:00

DOI: 10.3389/fped.2023.1146089 · PMC10185835